A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

Summary

This is a phase I/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of BPI-361175 tablets in patients with advanced solid tumors including advanced Non-small cell Lung cancer (NSCLC).This is a three-stage study, consisting of Phase Ia dose escalation, Phase Ib dose expansion and pivotal Phase II Study. The pivotal Phase II study will be designed based on data generated from the Phase I studies.

Timeline

Start

2021-07-21

Primary completion

2023-06-30

Completion

2023-12-31

Drugs

Indications